1st Quarter - Report
RARE DISEASE COMPANY COALITION for RARE DISEASE COMPANY COALITION
Income
—
Expenses
$110,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals
| Lobbyist | Covered position, as disclosed |
|---|---|
| STACEY FRISK | — |
| YOKO ROSENBAUM | — |
| GABBI SALMON New | Legislative Intern, Sen. Lamar Alexander. |
Trade (domestic/foreign) TRD
Proclamation 11020 - Section 232 Pharmaceutical Tariffs
| Lobbyist | Covered position, as disclosed |
|---|---|
| STACEY FRISK | — |
| GABBI SALMON New | Legislative Intern, Sen. Lamar Alexander. |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.